A cura di Alessandra Russo. Specialista in Tossicologia Medica. Messina
|
Principio attivo |
Effetto |
|
Acido aminolevulinico (1) |
Possibile aumento del rischio di reazioni cutanee fototossiche |
|
Antiacidi a base di alluminio o magnesio (2) |
Possibile riduzione dell’efficacia della moxifloxacina |
|
Corticosteroidi (3) |
Possibile aumento del rischio di rottura del tendine |
|
Donepezil (4,5) |
Possibile aumento del rischio di prolungamento dell’intervallo QT e di torsione di punta |
|
Ferro (6) |
Possibile riduzione dell’efficacia della moxifloxacina |
|
Idrossiclorochina (7) |
Possibile aumento del rischio di prolungamento dell’intervallo QT |
|
Lantanio carbonato (8) |
Possibile riduzione della biodisponibilità della moxifloxacina |
|
Rasagilina (9) |
Possibile aumento dell’esposizione a rasagilina |
|
Rifampicina (10) |
Possibile riduzione delle concentrazioni plasmatiche di moxifloxacina |
|
Sucralfato (11) |
Possibile riduzione dell’efficacia della moxifloxacina |
|
Warfarin (12-15) |
Possibile aumento del rischio di sanguinamento |
|
Zinco (16) |
Possibile riduzione dell’efficacia della moxifloxacina |
Bibliografia
- Product Information: GLEOLAN powder for oral solution, aminolevulinic acid HCl powder for oral solution. NX Development Corp (per FDA), Miami, FL, Jun, 2017.
- Stass H, et al. Evaluation of the influence of antacids and h2 antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinetic 2001; 40: 39-48.
- van der Linden PD, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163: 1801-1807.
- Takaya T, et al. Torsades de Pointes with QT prolongation related to donepezil use. J Cardiol 2009; 54: 507-511.
- Tanaka A. Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. Intern Med 2009; 48: 1219-1223.
- Product Information: Avelox(TM), moxifloxacin hydrochloride. Bayer Corporation, West Haven, CT, 09/2003.
- Product Information: PLAQUENIL(R) oral tablets, hydroxychloroquine sulfate oral tablets. Concordia Pharmaceuticals Inc (per DailyMed), Kansas City, MO, Sep, 2019.
- Product Information: FOSRENOL(R) oral chewable tablets oral powder, lanthanum carbonate oral chewable tablets oral powder. Shire US Inc. (per FDA), Wayne, IN, Sep, 2014.
- Product Information: AZILECT(R) oral tablets, rasagiline mesylate oral tablets. Teva Pharmaceuticals (per FDA), North Wales, PA, May, 2014.
- Nijland HM, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001-1007.
- Stass H, et al. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40: 49-55.
- Baillargeon J, et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med 2012; 125: 183-189.
- Arnold LM. Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy 2005; 25: 904-907.
- Elbe DH. Moxifloxacin-warfarin interaction: a series of five case reports. Ann Pharmacother 2005; 39: 361-364.
- O’Connor KA. The interaction of moxifloxacin and warfarin in three elderly patients. Eur J Intern Med 2003; 14: 255-257.
- Product Information: Avelox(TM), moxifloxacin hydrochloride. Bayer Corporation, West Haven, CT, 11/2000.